Cardiometabolic features of polycystic ovary syndrome

被引：0
|
作者：
Leslie K Hoffman
David A Ehrmann
机构：
[1] LK Hoffman is a Fellow,Department of Medicine
[2] and DA Ehrmann is a Professor of Medicine,undefined
[3] in the Section of Endocrinology,undefined
[4] Diabetes and Metabolism,undefined
[5] University of Chicago,undefined
[6] Chicago,undefined
[7] IL,undefined
[8] USA.,undefined
来源：
Nature Clinical Practice Endocrinology & Metabolism | 2008年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Polycystic ovary syndrome (PCOS) affects up to 10% of women and features a range of hormonal and metabolic abnormalities, many of which are associated with increased cardiovascular risk. The authors of this article urge clinicians to be aware of this risk when dealing with even young women who have PCOS.
引用
收藏
页码：215 / 222
页数：7
相关论文
共 50 条
  • [21] Adverse Cardiometabolic Outcomes in Men With Sisters With Polycystic Ovary Syndrome
    Kanina, Aleksandra
    Stener-Victorin, Elisabet
    Butwicka, Agnieszka
    Oberg, Anna Sara
    Rosenqvist, Mina A.
    Cesta, Carolyn E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025,
  • [22] Clinical and metabolic features of polycystic ovary syndrome
    Li, Lin
    Yang, Dongzi
    Chen, Xiaoli
    Chen, Yaxiao
    Feng, Shuying
    Wang, Liangan
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2007, 97 (02) : 129 - 134
  • [23] Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome
    Nandalike, Kiran
    Agarwal, Chhavi
    Strauss, Temima
    Coupey, Susan M.
    Isasi, Carmen R.
    Sin, Sanghun
    Arens, Raanan
    SLEEP MEDICINE, 2012, 13 (10) : 1307 - 1312
  • [24] Polycystic Ovary Syndrome-Is the Cardiometabolic Risk Increased After Menopause?
    Dokras, Anuja
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2017, 24 (12): : 1421 - 1422
  • [25] Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention
    Osibogun, Olatokunbo
    Ogunmoroti, Oluseye
    Michos, Erin D.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2020, 30 (07) : 399 - 404
  • [26] VISFATIN AS A POTENTIAL CARDIOMETABOLIC RISK FACTOR IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
    Koleva-Tyutyundzhieva, D.
    Ilieva-Gerova, M.
    Deneva, T.
    Nikolova, J.
    Orbetzova, M.
    ATHEROSCLEROSIS, 2023, 379 : S104 - S104
  • [27] Temporal Development of Cardiometabolic Complications in A Hyperandrogenemic Model of Polycystic Ovary Syndrome
    Pruett, Jacob E.
    Everman, Steven
    Romero, Damian G.
    Cardozo, Licy L. Yanes
    FASEB JOURNAL, 2022, 36
  • [28] Polycystic ovary syndrome as a gender-specific cardiometabolic risk factor
    van Baal, Lukas
    Tan, Susanne
    INNERE MEDIZIN, 2023, 64 (07): : 642 - 648
  • [29] Effect of the Mediterranean Diet on Cardiometabolic Biomarkers in Women with Polycystic Ovary Syndrome
    Mekki, K.
    Benharrats, L.
    Senouci, A.
    ANNALS OF NUTRITION AND METABOLISM, 2021, 77 : 6 - 6
  • [30] Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome
    Lempesis, Ioannis G.
    Apple, Samuel J.
    Duarte, Gustavo
    Palaiodimos, Leonidas
    Kalaitzopoulos, Dimitrios Rafail
    Dalamaga, Maria
    Kokkinidis, Damianos G.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2023, 39 (06)
12345